The Covid-19 vaccine developed by Pfizer and BioNTech is likely to protect against a more infectious variant of the virus, which was discovered in Britain and has spread around the world, according to results of further lab tests released on Wednesday.
The encouraging results, based on an analysis of blood of participants in trials, are based on more extensive analysis than those released by the US drugmaker last week.
Last week, Pfizer said a similar laboratory study showed the vaccine was effective against one key mutation, called N501Y, found in both of the highly transmissible new variants spreading in Britain and South Africa.
The latest study, which has not yet been peer reviewed, was conducted on 10 mutations, which are characteristic of the variant known as B117 identified in Britain.
LEAVE A COMMENT Your email address will not be published. Required fields are marked*
Word up! Scrabble marks UK lockdown easing with light show
WHO, agencies urge countries to suspend sale of live wild mammals at markets
Russians celebrate 60 years since Gagarin's spaceflight
Nomadland wins big at Bafta awards
Prince Philip’s ceremonial funeral on April 17
Charles hails ‘dear papa’ for devoted service
Prince Philip's ceremonial funeral on Apr 17
‘What a life!’ Britain pays tribute to Prince Philip
New vaccine probe worsens Europe’s Covid-19 troubles